Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Mallinckrodt
Johnson and Johnson
Dow
Merck

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for PF-04457845

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug PF-04457845: Sponsors, patents, clinical trial progress

PF-04457845 is an investigational drug.

There have been 9 clinical trials for PF-04457845. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2009.

The most common disease conditions in clinical trials are Chronic Pain, Stress Disorders, Post-Traumatic, and Acute Pain. The leading clinical trial sponsors are Pfizer, Yale University, and National Institute on Drug Abuse (NIDA).

There are four US patents protecting this investigational drug and ninety-two international patents.

Recent Clinical Trials for PF-04457845
TitleSponsorPhase
A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress DisorderPfizerPhase 2
FAAH Inhibitor Trial for Adults With Tourette SyndromeTourette Association of AmericaPhase 2
FAAH Inhibitor Trial for Adults With Tourette SyndromeYale UniversityPhase 2

See all PF-04457845 clinical trials

Clinical Trial Summary for PF-04457845

Top disease conditions for PF-04457845
Top clinical trial sponsors for PF-04457845

See all PF-04457845 clinical trials

US Patents for PF-04457845

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-04457845   See Pricing Biaryl ether urea compounds Pfizer Inc. (New York, NY)   See Pricing
PF-04457845   See Pricing Sulfonamide derivatives Pfizer Limited (Sandwich, GB) Icagen, Inc. (Durham, NC)   See Pricing
PF-04457845   See Pricing Sulfonamide derivatives Pfizer Limited (Sandwich, GB) Icagen, Inc. (Durham, NC)   See Pricing
PF-04457845   See Pricing Sulfonamide derivatives Pfizer Limited (Sandwich, GB) Icagen, Inc. (Durham, NC)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-04457845

Drugname Country Document Number Estimated Expiration Related US Patent
PF-04457845 African Regional IP Organization (ARIPO) 2780 2026-10-18   See Pricing
PF-04457845 Argentina 063331 2026-10-18   See Pricing
PF-04457845 Austria 493984 2026-10-18   See Pricing
PF-04457845 Australia 2007311591 2026-10-18   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Mallinckrodt
Harvard Business School
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.